A worldwide survey of 99 oncologists highlights real-world clinical strategies and multidisciplinary approaches for managing nausea, fatigue, and pulmonary toxicities ...
A cross-sectional study of 206 patients indicates that illness acceptance, social support, and self-efficacy are significantly linked to quality of ...
A retrospective cohort study found that patients with HER2-positive breast cancer underwent significantly more chemotherapy sessions than those with HER2-negative ...
Researchers profiled extracellular vesicles from obese adipose tissue using untargeted proteomics, identifying shared molecular pathways and subtype-specific prognostic protein candidates ...
A systematic review and meta-analysis of over one million breast cancer patients estimates the pooled reported proportion of lung metastases ...
A systematic review and meta-analysis of eight randomized controlled trials demonstrates that adding pertuzumab to standard therapies significantly improves progression-free ...
A perspective in Amino Acids argues that hormone receptor status defines distinct biological subtypes within HER2-positive breast cancer, influencing survival ...
A dynamic total-body PET/CT study of Ga-HER2 Affibody in HER2-positive breast cancer patients measured organ biodistribution, an effective dose of ...
Researchers built a single automated cassette workflow that produces, purifies and radiolabels zirconium-89 DFO-trastuzumab, achieving 100% radiochemical purity by HPLC ...
A survey of 74 patients with HER2-positive breast cancer in Australia and the United States found 74.3% were likely to ...
A retrospective Indian analysis of 101 patients reports real-world efficacy and safety outcomes for the trastuzumab emtansine biosimilar UJVIRA in ...
A seven-year follow-up of the PROTECT HER2 trial found that prophylactic carvedilol offered no significant long-term cardiovascular benefit in early-stage ...
A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...
A published case report describes curative breast tumour removal performed during combined ECMO and Impella support in a woman who ...
A multicenter Chinese real-world cohort found that adjuvant T-DM1 was associated with better early invasive disease-free survival than trastuzumab plus ...
An analysis of 81 Ethiopian breast cancer tissue samples associated higher immune-cell and PD-L1 measures with non-luminal subtypes and grade ...
A retrospective cohort of 450 East Asian patients with HER2-positive breast cancer found that subcutaneous neoadjuvant trastuzumab was associated with ...
The Alliance for Clinical Trials in Oncology marks Breast Cancer Awareness Month with eight active trials spanning treatment de-escalation, survivorship ...
A prospective study finds that 68Ga-HER2 PET/CT scans after just two cycles of neoadjuvant therapy can predict which HER2-positive breast ...
A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...
